Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DB25FZS11
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $8,623
Award facts
- Contract value 100% obligated
- $8,622.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on May 28, 2025, with an ultimate completion date of May 29, 2025, represents a standard pharmaceutical procurement under the DLA's medical supply chain operations. The award carries no set-aside designation, demonstrating the contractor's competitive positioning within the federal pharmaceutical market.
DMS Pharmaceutical Group holds a substantial single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and extending through November 2026, which serves as the vehicle for this delivery order. This IDC enables the agency to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. The contractor's established role as a federal pharmaceutical supplier, combined with its woman-owned small business status, positions it as a critical node in the defense medical supply chain, particularly for oncology treatments and specialty medications like Xtandi, a prostate cancer therapeutic.
Quick answers
Who was awarded contract SPE2DB25FZS11?
SPE2DB25FZS11 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on May 28, 2025.
How much is contract SPE2DB25FZS11 worth?
The government has obligated $8,623 on SPE2DB25FZS11.
Is contract SPE2DB25FZS11 an order under another contract?
Yes. SPE2DB25FZS11 is a delivery order under SPE2DB22D9244, an indefinite delivery contract.
Was contract SPE2DB25FZS11 competed?
The extent of competition for SPE2DB25FZS11 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award